Frontlight ResearchEarly access
Taking peoplePhase 2
Tildrakizumab for chronic spontaneous urticaria that has not responded to treatment
Tests tildrakizumab in adults with hard-to-treat chronic spontaneous urticaria, tracking hive symptoms.
Key facts
- Who runs it
- Philipps-Universitaet Marburg
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 18 people, planned
- Started
- 2 Mar 2026
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic spontaneous urticaria (hives with no clear trigger) that continues despite antihistamine treatment. It tests tildrakizumab.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Chronic spontaneous urticaria for at least 6 weeks, with hives and itching for at least 6 weeks despite H1 antihistamine treatment. Urticaria activity score UAS7 (range 0–42) of 16 or more.
- Earlier treatment
- People must be taking H1 antihistamines (H1 blockers) at a stable dose. People cannot join if they had immune-suppressing or immune-changing treatment. For omalizumab, the last dose must be at least 3 months before the start.
- Biomarker or test result
- An IL-17-mediated T-cell immune profile, shown by a blood test called flow cytometry.
Main reasons for not taking part
- Hives mainly triggered by things like cold or pressure
- Current autoimmune disease, such as rheumatoid arthritis, lupus or multiple sclerosis
- Past cancer, except treated non-melanoma skin cancer
- Active or latent tuberculosis, or another active widespread skin disease like psoriasis or atopic eczema
- Pregnancy, breastfeeding, or a live vaccine within 1 month before the study or planned
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age ≥ 18 years
- CSU for ≥ 6 weeks, hives and itching for ≥ 6 weeks despite H1 antihistamine treatment at screening
- Must be on stable co-medication with H1 blockers
- IL-17-mediated T-cellular immune profile as determined by flow cytometry
- UAS7 (range 0–42) of ≥ 16
- Signed written informed consent
- For women of childbearing potential (WOCBP): A negative result in highly sensitive pregnancy test and willingness of additional pregnancy testing monthly up to the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Tildrakizumab is achieved after 17 weeks after the last administration of Tildrakizumab
- Willingness of women of childbearing potential (WOCBP) to use highly effective methods of contraception* during treatment and until the end of relevant systemic exposure. End of relevant systemic exposure for the IMP Tildrakizumab is achieved after 17 weeks after the last administration of Tildrakizumab
Who cannot take part
- Immunization with live vaccines (planned or within 1 month prior to the study)
- Current/active autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematodes, multiple sclerosis etc
- History of malignancy (with the exception of adequately treated non-melanoma skin cancer)
- Active or latent tuberculosis
- Any active generalized skin disease like psoriasis or atopic eczema
- Primarily subtype of inducible chronic urticaria (e.g. cold, pressure)
- Participation in other clinical trials
- Immunosuppressive or -modulatory treatments, including omalizumab, the latter for less than 3 half-lives (that means 3 months) before starting treatment at baseline
- Pregnant women
- Breast-feeding women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the change in UAS (Urticaria Activity Score) 7 from baseline to week 20.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)
- Plain-language title
- Tildrakizumab for chronic spontaneous urticaria that has not responded to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 2 November 2026